

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8051302

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
JONATHAN E. WILSON	07/03/2023
JAMES E. AUDIA	06/27/2023
JACOB I. STUCKEY	07/10/2023
RECEIVING PARTY DATA	
Name:	FLARE THERAPEUTICS INC.
Street Address:	215 FIRST STREET
Internal Address:	SUITE 150
City:	CAMBRIDGE
State/Country:	MASSACHUSETTS
Postal Code:	02142
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	18130121
CORRESPONDENCE DATA	
Fax Number:	(617)607-9200
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6174496500
Email:	gcoy@mccarter.com
Correspondent Name:	MICHAEL J. DEGRAZIA
Address Line 1:	MCCARTER & ENGLISH, LLP
Address Line 2:	265 FRANKLIN STREET
Address Line 4:	BOSTON, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	132266-00303
NAME OF SUBMITTER:	MICHAEL J. DEGRAZIA, PH.D.
SIGNATURE:	/MICHAEL J. DEGRAZIA, PH.D./
DATE SIGNED:	07/11/2023
Total Attachments: 5	
source=132266-00303 Fully Executed Assignment#page1.tif	
source=132266-00303 Fully Executed Assignment#page2.tif	

source=132266-00303 Fully Executed Assignment#page3.tif

source=132266-00303 Fully Executed Assignment#page4.tif

source=132266-00303 Fully Executed Assignment#page5.tif

ASSIGNMENT - WORLDWIDE

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each undersigned inventor (hereinafter referred to singly and collectively as "ASSIGNOR") has sold, assigned, and transferred, and hereby sells, assigns, and transfers, unto

Flare Therapeutics Inc.
215 First Street, Suite 150
Cambridge, Massachusetts 02142
United States of America

(hereinafter referred to as "ASSIGNEE") its successors and assigns, the full and exclusive right, title and interest for the United States, its territories and possessions, and all foreign countries in and to this invention relating to

PPARG INVERSE AGONISTS AND USES THEREOF

as set forth in the following Patent Applications:

U.S. Patent Application No. 18/130,121, filed April 3, 2023
International Application No. PCT/CN2022/129034, filed November 1, 2022
Argentine Patent Application No. 20220102982, filed November 1, 2022
Taiwanese Patent Application No. 111141614, filed November 1, 2022

which claim the benefit of the following Applications:

United States Provisional Application No. 63/347,671, filed June 1, 2022
United States Provisional Application No. 63/274,596, filed November 2, 2021

Including (a) all other applications for Letters Patent of the United States and countries foreign thereto for above-identified invention or inventions, (b) all Letters Patent which may issue from said applications in the United States and countries foreign thereto, (c) all divisions, continuations, reissues, and extensions of said applications and Letters Patent, and (d) the right to claim for any of said applications the full benefits and priority rights under the International Convention and any other international agreement to which the United States adheres; such right, title, and interest to be held and enjoyed by ASSIGNEE, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment not been made.

ASSIGNOR HEREBY AUTHORIZES ASSIGNEE to file patent applications in any or all countries on the above-identified invention or inventions in the name of the undersigned or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable under the International Convention or otherwise.

ASSIGNOR HEREBY AUTHORIZES AND REQUESTS the Commissioner of Patents and Trademarks to issue said Letters Patent to ASSIGNEE as assignee of the entire interest, for the sole use and benefit of ASSIGNEE, its successors and assigns.

ASSIGNOR HEREBY AGREES (a) to communicate to ASSIGNEE, its successors and assigns, or their representative or agents, all facts and information known or available to ASSIGNOR respecting said invention or inventions, including evidence for interference, reexamination, reissue, opposition, revocation, extension, or infringement purposes or other legal, judicial, or administrative proceedings, whenever requested by ASSIGNEE; (b) to testify in person or by affidavit as required by ASSIGNEE, its successors and assigns, in any such proceeding in the United States or a country foreign thereto; (c) to execute and deliver, upon request by ASSIGNEE, all lawful papers including, but not limited to, original, divisional, continuation, and reissue applications, renewals, assignments, powers of attorney, oaths, affidavits, and declarations, depositions; and (d) to provide all reasonable assistance to ASSIGNEE, its successors and assigns, in obtaining and enforcing proper title in and protection for said invention or inventions under the intellectual property laws of the United States and countries foreign thereto.

ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.


ASSIGNOR HEREBY GRANTS to the law firm of **McCarter & English, LLP** the power and authority to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

ASSIGNOR UNDERSTANDS AND AGREES that the attorneys and agents of the law firm of **McCarter & English, LLP** do not personally represent ASSIGNOR OR ASSIGNOR's legal interests, but instead represent the interests of ASSIGNEE; since said attorneys and agents cannot provide legal advice to ASSIGNOR with respect to this Assignment, ASSIGNOR acknowledges its right to seek its own independent legal counsel.

Executed this 3rd day of July, 2023.


Jonathan E. Wilson

Executed this 27th day of June, 2023



James E. Audia

Witness Signature: _____

Date: _____

Printed Name: _____

Executed this 10th day of July, 2023.



Jacob L. Stuckey